LivaNova PLC expects its Caisson transcatheter mitral valve replacement (TMVR) system to earn a CE mark in 2020, based on results of the INTERLUDE registry.
Enrollment in INTERLUDE, a single-arm study planned for 75 patients, has begun in Canada and will enroll patients in Europe and North America, Paul Buckman, LivaNova's General Manager for TMVR,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?